Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump
pharmafile | May 10, 2019 | News story | Medical Communications | Gilead, HIV, PrEP, Trump, Truvada, descovy
Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions between the Trump Administration” and the California firm.
Gilead Sciences will give preventative HIV drug Truvada to uninsured individuals who are at risk of being infected with HIV, Health and Human Services Secretary Alex Azar said.
The agreement will last until at least the end of 2025 and may continue through to December 31 2030.
Under the terms of the agreement Gilead will donate Truvada to those at risk until Gilead’s second-generation PrEP drug Descovy hits the market, at which point Gilead will begin to donate Descovy – otherwise Gilead will give away Truvada for the whole 11 year period.
The agreement comes as part of the Trump administration’s plan to end the HIV epidemic in America by 2030.
Gilead’s Truvada currently carries a list price of $20,000 a year. The government has agreed to cover costs associated with the distribution of the drug.
Alex Azar commented: “Securing this commitment is a major step in the Trump Administration’s efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030.”
“Under President Trump’s leadership, HHS worked with Gilead to secure preventative medication for individuals who might otherwise not be able to access or afford this important treatment.”
“The majority of Americans who are at risk and who could protect themselves with PrEP are still not receiving the medication. This agreement will help close that gap substantially and deliver on President Trump’s promise to end the HIV epidemic in America.”
Donald Trump tweeted: “Great news today: My Administration just secured a historic donation of HIV prevention drugs from Gilead to help expand access to PrEP for the uninsured and those at risk. Will help us achieve our goal of ending the HIV epidemic in America!”
Louis Goss
Related Content
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …
